Poster Session B
Tuesday, Dec. 11
5:25 p.m.-7:25 p.m.

B01 Inhibition of RAS signaling and tumorigenesis through targeting vulnerabilities in RAS biochemistry. John P. O’Bryan. MUSC, UIC, Charleston, SC.

B02 Dissecting tumor cell heterogeneity to identify therapeutic vulnerabilities in Kras-mutant lung cancer. Aparna Padhye, University of Texas MD Anderson Cancer Center, Houston, TX.

B03 Biologic and biochemical interactions of NF1 GAP on KRAS G13x mutations. Dana Rabara, Frederick National Laboratory for Cancer Research, Frederick, MD.

B04 High-level expression of oncogenic KRAS is required to transform LKB1 mutant tissue in vivo. Briana B. Rackley, Emory University, Atlanta, GA.

B05 ASN007, an oral ERK1/2 inhibitor, shows strong antitumor activity across a panel of KRAS subtype mutant cancer models. Sanjeeva P. Reddy, Asana BioSciences, Lawrenceville, NJ.

B06 ING2 loss sensitizes KRAS-mutated NSCLC to WEE1 inhibition through regulation of CHK1 expression. Charles Ricordel, Université de Rennes 1, Rennes, France.

B07 Inhibition of Ras signalling by targeting Son of Sevenless with Affimers. Sophie E. Saunders, University of Leeds, Leeds, United Kingdom.

B08 ETC inhibitors alter oncogenic KRAS signal transduction. Kanika Sharma, Frederick National Laboratory for Cancer Research, Frederick, MD.

B09 Combining proteomics and genetic screens to identify KRAS synthetic lethal interactions. Shikha S. Sheth, Cancer Research Institute, Beth Israel Deaconess Cancer Center and Department of Medicine, Harvard Medical School, Boston, MA.

B10 Modeling the genetic heterogeneity of KRAS mutant lung adenocarcinomas for therapeutic discovery. Kate D. Sutherland, The Walter and Eliza Hall of Medical Research, Melbourne, VIC, Australia.

B11 O-GlcNAcylation is required for mutant KRAS-induced lung tumorigenesis. Phuoc T. Tran, Johns Hopkins University School of Medicine, Baltimore, MD.

B12 DOCK1 as a novel target for controlling RAS-driven cancer cell survival and invasion. Takehito Uruno, Kyushu University, Medical Institute of Bioregulation, Fukuoka-city, Japan.

B13 Parallel targeting of RAF/MEK/ERK pathway in RAS-mutant embryonal rhabdomyosarcoma. Angelina V. Vaseva, Greehey Children's Cancer Research Institute, The University of Texas Health Science Center, San Antonio, TX.
Poster Session B
Tuesday, Dec. 11
5:25 p.m.-7:25 p.m.


B15 Dabrafenib-trametinib-induced pyrexia successfully treated with colchicine. Jesus Vera, Mayo Clinic, Rochester, MN.

B16 Role of RasGRF2 in AnxA6-mediated growth of TNBC cells. Diva S. Whalen, Meharry Medical College, Nashville, TN.

B17 MEK inhibition induces myogenic differentiation in RAS-driven rhabdomyosarcoma. Marielle E. Yohe, NCI, Bethesda, MD.

B18 Clostridium perfringens lethal toxin specifically targets RAS and disrupts RAS signaling pathway. Maria Abreu-Blanco, Frederick National Laboratory for Cancer Research, Frederick, MD.


B20 Unbiased high-throughput screenings to identify combination therapies targeting RAS-mutated colorectal cancer. Rajat Bhattacharyya, University of Texas MD Anderson Cancer Center, Houston, TX.

B21 Cancer-specific intracellular delivery of therapeutic antibodies against KRAS. Kathlynn C. Brown, SRI International, Harrisonburg, VA.


B23 Insight towards therapeutic susceptibility of KRAS mutant cancers from MRTX1257: A prototype selective inhibitor of KRAS G12C. James G. Christensen, Mirati Therapeutics, San Diego, CA.


B25 Combined proteomic and genetic interaction mapping reveals new Ras pathway effectors and regulators. Peter K. Jackson, Stanford University, Stanford, CA.

B27 A DARPin-based toolbox to understand and treat RAS-addicted cancers. Jonas N. Kapp, University of Zurich, Zurich, Switzerland.

B28 Direct targeting oncogenic Ras mutants by IgG-format cytosol-penetrating antibody. Yong-Sung Kim, Ajou University, Suwon, Republic of Korea.

B29 SHANK3 in oncogenic RAS signaling. Johanna Lilja, Turku Centre for Biotechnology, University of Turku, Turku, Finland.


B31 Combination inhibitor strategies targeting KRAS effector signaling in KRAS-mutant pancreatic cancer. Irem Ozkan-Dagliyan, University of North Carolina, Chapel Hill, NC.

B32 Silencing of oncogenic KRAS by a mutant-favoring short interfering RNA. Bjoern Papke, University of North Carolina at Chapel Hill, Chapel Hill, NC.

B33 Inhibition of Ras using Affimers. Ajinkya Rao, University of Leeds, Leeds, United Kingdom.

B34 Targeted destruction of endogenous K-RAS using an Affinity directed PROtein Missile (AdPROM). Sascha O. M. Roth, MRC Protein Phosphorylation and Ubiquitylation Unit, School of Life Sciences, University of Dundee, Dundee, United Kingdom.


B36 Berberine induces apoptosis in cervical carcinoma cells by inducing DNA damage and inhibition of RAS MAPK pathway. Mayank Singh, All India Institute of Medical Sciences Delhi, New Delhi, India.

B37 Development of inhibitors of the activated form of KRAS G12C. Michelle L. Stewart, Warp Drive Bio, Cambridge, MA.

B38 Ras clipping by bacterial toxin RRSP reduces viability and proliferation of Ras-dependent cancer cell lines in 2D and 3D in vitro models. Vania Vidimar, Northwestern University, Chicago, IL.

B39 Characterization of the interaction between KRAS and Argonaute 2. Jessica Waninger, University of Michigan, Ann Arbor, MI.
Poster Session B  
Tuesday, Dec. 11  
5:25 p.m.-7:25 p.m.

B40 Role of mutant HRAS in growth and drug sensitivity of head and neck squamous cell cancers (HNSCC). Adrienne D. Cox, University of North Carolina at Chapel Hill, Chapel Hill, NC.

B43 A systems biology approach to elucidate the mechanism of EGFR inhibitor sensitivity in mutant KRAS-driven colorectal cancer. Thomas McFall, Salk Institute, La Jolla, CA.

B44 KRAS and RAS signaling network is co-regulated and can be therapeutically blocked by targeting eIF4A dependent translation program. Kamini Singh, Cancer Biology and Genetics Program, Memorial Sloan Kettering Cancer Center, New York, NY.

B45 Surveillance of RAS-RAF dynamics in vivo: Tracking activity conformations and drug-induced interactions. Eduard Stefan, University of Innsbruck, Innsbruck, Austria.

B46 Systems modeling of Ras reveals systems mechanisms that dictate response to treatment. Edward C. Stites, Salk Institute for Biological Studies, La Jolla, CA.

B47 Systems-level dissection of tumor-macrophage crosstalk in ovarian cancer resistance to MEK inhibition. Stephanie J. Wang, Massachusetts Institute of Technology, Cambridge, MA.

B48 Anti peptide-HLA (TCR-like) antibodies specific for the KRAS G12V neoantigen. Ben Kiefel, Affinity Biosciences, Melbourne, VIC, Australia.

B49 “Triple wild-type” co-mutational profile in early-stage KRAS-mutant lung cancer. Colin R. Lindsay, University of Manchester, Manchester, United Kingdom.

B50 ERK MAPK inhibition enhances the immunogenicity of KRAS-mutant colorectal cancer. Meagan B. Ryan, Massachusetts General Hospital Cancer Center, Boston, MA.

B51 MAPK regulation of an innate immune response in KRAS-mutant lung adenocarcinoma. Daniel Sisler, University of Colorado-Anschutz Medical Campus, Aurora, CO.

B52 KRAS-IRF2 axis drives immune suppression and immune therapy resistance in colorectal cancer. Alan Wang, University of Texas MD Anderson Cancer Center, Houston, TX.

B53 Differential response of distinct KRAS mutants to SHP2 inhibition. Sara Mainardi, Molecular Carcinogenesis Division, The Netherlands Cancer Institute, Amsterdam, The Netherlands.